ACTIV-1 IM - Clinical Trial

What is the Purpose of this Study?

We are doing this study to test the ability of various drugs to improve health outcomes for people with COVID-19.

What is the Condition Being Studied?

COVID-19

Who Can Participate in the Study?

Adults currently hospitalized with severe COVID-19 complications

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
--Be randomized to 1 of 3 Groups:
---Group 1 will test the study drug Abatacept vs. placebo (infusion into your vein)
---Group 2 will test the study drug Infliximab vs. placebo (infusion into your vein)
---Group 3 will test the study drug Cenicriviroc vs. placebo (60 days of pills)
-Give blood samples
-Participate in clinic and phone visits following discharge from hospital
-All patients will also get Remdesivir

*A placebo is a harmless inactive treatment that does not have medicine in it

Study Details

Full Title
¿Randomized Master Protocol for Immune Modulators for Treating COVID-19 (ACTIV-1 IM)¿
Principal Investigator
Infectious Disease Specialist
Protocol Number
IRB: PRO00106819
NCT: NCT04593940
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center
MyResearchPartners@duke.edu
or
919-681-5698